The Orlando, FL-based pharma firms develops transdermal drug products. Lead candidate is an abuse-deterrent transdermal fentanyl for the management of chronic pain that it says is more abuse-deterrent than currently available fentanyl patches. Net proceeds from the offering will fund preclinical and clinical development.
Shares currently trade on the OTCQB Venture Market. The company has applied for uplisting to the Nasdaq Capital Market.